Cover Image
市場調查報告書

生物模擬的全球市場 2015-2021年:企業簡介、佔有率、趨勢、分析、機會、區分、預測

Global Biosimulation Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 - 2022

出版商 Occams Business Research & Consulting Pvt. Ltd. 商品編碼 346121
出版日期 內容資訊 英文 140 Pages
商品交期: 請詢問到貨日
價格
Back to Top
生物模擬的全球市場 2015-2021年:企業簡介、佔有率、趨勢、分析、機會、區分、預測 Global Biosimulation Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 - 2022
出版日期: 2016年04月09日 內容資訊: 英文 140 Pages
簡介

生物模擬市場上需求,被預測根據個體化醫療的利用擴大等要素,增加到在預測期間內。

本報告提供全球生物模擬市場相關調查、市場定義與概要、價值鏈、市場成長的各種影響因素及市場機會分析、各產品/終端用戶/應用/藥物研發/地區與主要國家趨勢及市場規模的變化與預測、競爭環境,以及主要企業的簡介等彙整。

第1章 簡介

第2章 市場概要

  • 市場定義、範圍
  • 主要調查結果
  • 參數分析
    • 個體化醫療市場
    • R&D的投資:各企業
    • 地區整體醫療費
    • 新興經濟國的可支配所得
  • 主要市場考察
    • 新興經濟國前3名
    • 收益產生區分前3名
    • 市場趨勢
    • 成功策略
    • 開發平台分析
  • R&D情形
  • 競爭分析
    • 市場佔有率分析
    • 主要的成功策略
    • 案例研究
  • 價值鏈分析
  • 主要的購買標準
  • 策略建議
  • 策略性結論

第3章 市場決策因素

  • 市場成長的促進要素
    • 個體化醫療的利用擴大
    • R&D
    • 醫藥品、生物科技產業的成長
    • 改良的模擬、建模工具的發明
    • 慢性疾病的發病率的增加
  • 市場阻礙成長要素
    • 熟練專家的不足
    • 生物模擬軟體開發高額的H&D成本
    • 標準化工具、應用的不足
  • 市場機會
    • 人口高齡化促進醫藥新市場
    • 醫藥品企業間的聯盟
  • 市場課題
    • 生物學流程的有限知識
    • 成本高

第4章 部門分析

  • 專利市場
  • 競爭企業的市場
  • 替代市場

第5章 市場區隔

  • 全球生物模擬市場:各產品
    • 服務
    • 試設計軟體
    • PMBK建模
    • 毒性預測軟體
    • 分子模擬
  • 全球生物模擬市場:各終端用戶
    • 研究機關
    • 醫藥品生物科技企業
    • 法規當局
  • 全球生物模擬市場:各應用領域
    • 藥物研發
    • PK/PD
    • 臨床實驗
    • LI及LO
  • 全球生物模擬市場:各藥物研發
    • 臨床試驗前
    • 住院患者評估

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 其他的亞太地區
  • 其他地區

第7章 企業簡介

  • Certara USA, Inc.
  • Rhenovia Pharma Ltd.
  • Physiomics PLC
  • Genedata Ag
  • Entelos Holding Corporation
  • Chemical Computing Group, Inc.
  • Advanced Chemistry Development, Inc.
  • Schrodinger Inc.
  • Dassault Systemes SA
  • Simulation Plus Inc.
  • Biovia (Formerly Accelrys)
  • In silico biosciences
  • Inhibox
  • Leadinvent Technologies
  • Leadscope
  • Nimbus therapeutics
  • Open eye Scientific software
  • Physiomics Plc.
  • Rhenovia Pharma
  • Genedata

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: HAD-1261015

Biosimulation is explained as a computer-aided mathematical simulation of biological processes and systems and hence is an integral part of systems biology. The main aim of Biosimulation is model-based prediction of the behavior and the dynamics of biological systems e.g. the response of an organ or a single cell towards a chemical. It is a predictive tool and used in discovery stage to determine the future outcomes of current experimental trials.

The demand for Biosimulation market is expected to increase in forecasted period due to increase in the factors such as use of personalized medicine.

Factors that are driving the market are: Increase in the use of personalized medicine also continuous research and development is going on in the field which has led to the improvement and simulation of modeling tools, also the growth in the biotechnological and pharmaceutical industries has helped Biosimulation industry to grow. Also, the industry is expecting growth due to the boom in drugs market as a result of increase in ageing population and increasing number of chronic diseases. Some of the factors which are restraining the market are shortage of skilled professionals, higher cost of the process, lack of standardized tools and applications and limited knowledge about biological process.

The market of Biosimulation market is segmented on the basis of products, end user, application, drug development. Geographically the market is divided in to North America (US, Canada), Europe (UK, Italy, Spain, France, Germany, rest of Europe), Asia-Pacific (India, Japan, Australia, China, Korea, Rest of Asia Pacific) and Rest of World (Latin America, MENA and Africa). The key providers of biosimulation technology are Certara, Biovia, Dassault Systèmes.

Companies profile include

  • 1. Certara USA, Inc.
  • 2. Rhenovia Pharma Ltd.
  • 3. Physiomics PLC
  • 4. Genedata Ag
  • 5. Entelos Holding Corporation
  • 6. Chemical Computing Group, Inc.
  • 7. Advanced Chemistry Development, Inc.
  • 8. Schrödinger Inc.
  • 9. Dassault Systèmes SA
  • 10. Simulation Plus Inc.
  • 11. Biovia (Formerly Accelrys)
  • 12. In silico biosciences
  • 13. Inhibox
  • 14. Leadinvent Technologies
  • 15. Leadscope
  • 16. Nimbus therapeutics
  • 17. Open eye Scientific software
  • 18. Physiomics Plc.
  • 19. Rhenovia Pharma
  • 20. Genedata

This Occams Research Report covers

  • 1. Historical data
  • 2.Revenue forecasts, growth rates and CAGR up to 2022
  • 3.Industry Analysis
  • 4.Competitive Analysis
  • 5. Key geographic growth data

Table of Contents

1. Introduction

  • 1.1. Executive Summary
  • 1.2. Estimation methodology

2. Market overview

  • 2.1. Market definition and scope
  • 2.2. Key findings
  • 2.3. Parametric analysis
    • 2.3.1. Personalized medicine market
    • 2.3.2. Investment in R&D by various organizations
    • 2.3.3. Healthcare expenditure across geographies
    • 2.3.4. Disposable income of top emerging economies
  • 2.4. Key market insights
    • 2.4.1. Top 3 emerging countries
    • 2.4.2. Top 3 revenue generating segments
    • 2.4.3. Market trends
    • 2.4.4. Winning strategy
    • 2.4.5. Pipeline analysis
  • 2.5. R & D Scenario
  • 2.6. Competitive intelligence
    • 2.6.1. Market share analysis
    • 2.6.2. Top winning strategies
    • 2.6.3. Case study; top competitive moves
  • 2.7. Value chain analysis
  • 2.8. Key buying criteria
  • 2.9. Strategic recommendation
  • 2.10. Strategic conclusion

3. Market determinants

  • 3.1. Market driver
    • 3.1.1. Increased use of personalized medicine
    • 3.1.2. Research and development in the field
    • 3.1.3. Growth in pharmaceutical and biotechnological industries.
    • 3.1.4. Advent of improved simulation and modeling tools
    • 3.1.5. Growing incidence of chronic diseases.
  • 3.2. Market Restraints
    • 3.2.1. Shortage of skilled professionals
    • 3.2.2. High R&D costs of biosimulation software development
    • 3.2.3. Lack of standardized tools and applications
  • 3.3. Market opportunities
    • 3.3.1. Drive in drugs market due to ageing population
    • 3.3.2. Partnership among pharmaceutical players
  • 3.4. Market challenges
    • 3.4.1. Limited knowledge of biological process
    • 3.4.2. Higher cost

4. Sector analysis

  • 4.1. Parent market analysis
  • 4.2. Competitor market analysis
  • 4.3. Alternative market analysis

5. Market Segmentation

  • 5.1. Global Biosimulation market on the basis of products, 2014-2021,($ millions)
    • 5.1.1. Global Biosimulation market on the basis of services, 2014-2021,($ millions)
    • 5.1.2. Global Biosimulation market on the basis of Trial Design software, 2014-2021,($ millions)
    • 5.1.3. Global Biosimulation market on the basis of PBPK modeling, 2014-2021,($ millions)
    • 5.1.4. Global Biosimulation market on the basis of Toxicity prediction software, 2014-2021,($ millions)
    • 5.1.5. Global Biosimulation market on the basis of Molecular modeling and simulation software, 2014-2021,($ millions)
  • 5.2. Global Biosimulation market on the basis of end user, 2014-2021($ millions)
    • 5.2.1. Global Biosimulation market on the basis of Research institutes , 2014-2021,($ millions)
    • 5.2.2. Global Biosimulation market on the basis of Pharmaceutical biotechnological companies, 2014-2021,($ millions)
    • 5.2.3. Global Biosimulation market on the basis of Regulatory athourities, 2014-2021,($ millions)
  • 5.3. Global Biosimulation market on the basis of application, 2014-2021($ millions)
    • 5.3.1. Global Biosimulation market on the basis of Drug development, 2014-2021,($ millions)
    • 5.3.2. Global Biosimulation market on the basis of PK/PD, 2014-2021,($ millions)
    • 5.3.3. Global Biosimulation market on the basis of Clinical trials, 2014-2021,($ millions)
    • 5.3.4. Global Biosimulation market on the basis of Lead identification and Optimization, 2014-2021,($ millions)
  • 5.4. Global biosimulation market on the basis of Drug development,2014-2021($ millions)
    • 5.4.1. Global Biosimulation market on the basis of Preclinical testing, 2014-2021,($ millions)
    • 5.4.2. Global Biosimulation market on the basis of Inpatient validation, 2014-2021,($ millions)

6. Geographic analysis

  • 6.1. North America market, 2014-2021,($ millions)
    • 6.1.1. U.S Biosimulation market,2014-2021,($millions)
    • 6.1.2. Canada Biosimulation market,2014-2021,($millions)
  • 6.2. Europe Biosimulation market,2014-2021,($millions)
    • 6.2.1. U.K Biosimulation market,2014-2021,($millions)
    • 6.2.2. Germany Biosimulation market,2014-2021,($millions)
    • 6.2.3. France Biosimulation market,2014-2021,($millions)
    • 6.2.4. Spain market Biosimulation,2014-2021,($millions)
    • 6.2.5. Italy market Biosimulation,2014-2021,($millions)
  • 6.3. Asia Pacific
    • 6.3.1. China Biosimulation market ,2014-2021,($millions)
    • 6.3.2. India Biosimulation market,2014-2021,($millions)
    • 6.3.3. Korea Biosimulation market,2014-2021,($millions)
    • 6.3.4. Japan Biosimulation market,2014-2021,($millions)
    • 6.3.5. Australia Biosimulation market,2014-2021,($millions)
    • 6.3.6. Rest of APAC
  • 6.4. Rest of the world

7. Company Profiling

  • 7.1. Certara USA, Inc.
  • 7.2. Rhenovia Pharma Ltd.
  • 7.3. Physiomics PLC
  • 7.4. Genedata Ag
  • 7.5. Entelos Holding Corporation
  • 7.6. Chemical Computing Group, Inc.
  • 7.7. Advanced Chemistry Development, Inc.
  • 7.8. Schrödinger Inc.
  • 7.9. Dassault Systèmes SA
  • 7.10. Simulation Plus Inc.
  • 7.11. Biovia(Formerly Accelrys)
  • 7.12. In silico biosciences
  • 7.13. Inhibox
  • 7.14. Leadinvent Technologies
  • 7.15. Leadscope
  • 7.16. Nimbus therapeutics
  • 7.17. Open eye Scientific software
  • 7.18. Physiomics Plc.
  • 7.19. Rhenovia Pharma
  • 7.20. Genedata
Back to Top